{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:12:34Z","timestamp":1787785954009,"version":"build-2784847793"},"reference-count":79,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DHPS"],"DOI":"10.2147\/dhps.s348727","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:50:10Z","timestamp":1694404210000},"page":"103-112","source":"Crossref","is-referenced-by-count":26,"title":["Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Shaun","family":"O'Hagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Galway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e1004016","DOI":"10.1371\/journal.ppat.1004016","volume":"10","author":"Meng","year":"2014","journal-title":"PLoS Pathog"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.medmal.2018.01.008","volume":"48","author":"Haber","year":"2018","journal-title":"Med Mal Infect"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/archdischild-2021-322435","volume":"107","author":"Anderson","year":"2021","journal-title":"Arch Dis Child"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1542\/peds.2007-0788","volume":"120","author":"Bloemers","year":"2007","journal-title":"Pediatrics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e89186","DOI":"10.1371\/journal.pone.0089186","volume":"9","author":"Murray","year":"2014","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/cid\/cir928","volume":"54","author":"Kristensen","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40121-016-0130-1","volume":"5","author":"Igueras-Aloy","year":"2016","journal-title":"Infect Dis Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/INF.0000000000000924","volume":"35","author":"Haerskjold","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/irv.12770","volume":"14","author":"Nguyen-van-tam","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.vaccine.2020.01.020","volume":"38","author":"Driscoll","year":"2020","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/vaccines8020201","volume":"8","author":"Esteban","year":"2020","journal-title":"Vaccines"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/infdis\/jiz683","volume":"222","author":"Zhang","year":"2020","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"594898","DOI":"10.3389\/fped.2020.594898","volume":"8","author":"Bozzola","year":"2021","journal-title":"Front Pediatr"},{"key":"ref16","first-page":"46","volume":"2022","author":"Brusco","year":"2018","journal-title":"Commun Dis Intell"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"105666","DOI":"10.1016\/j.earlhumdev.2022.105666","volume":"174","author":"Messina","year":"2022","journal-title":"Early Hum Dev"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.vaccine.2015.05.093","volume":"34","author":"Modjarrad","year":"2016","journal-title":"Vaccine"},{"key":"ref19","unstructured":"U.S Food and Drug Administration. FDA news release, FDA approves first Respiratory Syncytial Virus (RSV) vaccine, arexvy approved for individuals 60 years of age and older; 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine. Accessed June 22, 2023."},{"key":"ref20","unstructured":"European Medicines Agency. First RSV vaccine to protect infants up to 6 months of age and older adults; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/news\/first-rsv-vaccine-protect-infants-6-months-age-older-adults. Accessed August 1, 2023."},{"key":"ref21","unstructured":"Pfizer. Pfizer press release, U.S. FDA approves ABRYSVO\u2122, Pfizer\u2019s vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults; 2023. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-abrysvotm-pfizers-vaccine-prevention. Accessed August 1, 2023."},{"key":"ref22","first-page":"1149","volume":"131","author":"Johnson","year":"1990","journal-title":"Endocrinology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.401547","volume":"195","author":"Kilham","year":"1977","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/tera.1420170117","volume":"17","author":"Ferm","year":"1978","journal-title":"Teratology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/00039896.1995.9935981","volume":"50","author":"Linn","year":"1995","journal-title":"Arch Environ Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1128\/AAC.31.7.1143","volume":"31","author":"Rodriguez","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"ref27","first-page":"204","volume":"138","author":"Bortolussi","year":"1988","journal-title":"Can Med Assoc J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJM199107043250105","volume":"325","author":"Smith","year":"1991","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0022-3476(05)82091-8","volume":"119","author":"Moler","year":"1991","journal-title":"J Pediatr"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","volume":"39","author":"Tejada","year":"2022","journal-title":"Adv Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ppul.21184","volume":"45","author":"Anak","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"ref32","volume-title":"Encyclopedia of Respiratory Medicine","year":"2006"},{"key":"ref33","volume-title":"Feigin and Cherry\u2019s Textbook of Pediatric Infectious Diseases","year":"2009"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93\u201399. doi:10.1542\/peds.99.1.93","DOI":"10.1542\/peds.99.1.93"},{"key":"ref35","volume-title":"Quah. International Encyclopedia of Public Health","year":"2017"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-3476(98)70056-3","volume":"133","author":"Simoes","year":"1998","journal-title":"J Pediatr"},{"key":"ref37","first-page":"525","volume":"22","author":"Oertel","year":"1996","journal-title":"Pediatr Nurs"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","volume":"7","author":"Sim\u00f5es","year":"2018","journal-title":"Infect Dis Ther"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531\u2013537. doi:10.1542\/peds.102.3.531","DOI":"10.1542\/peds.102.3.531"},{"key":"ref40","unstructured":"Public Health England. Chapter 27a: respiratory Syncytial Virus. In: Immunisation Against Infectious Disease (Green Book). London: Department of Health; 2015."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jinf.2005.08.003","volume":"52","author":"Harkensee","year":"2006","journal-title":"J Infect"},{"key":"ref42","unstructured":"Paediatric Formulary Committee. BNF for Children. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2022."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"CD013757","DOI":"10.1002\/14651858.CD013757.pub2","volume":"11","author":"Garegnani","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1055\/a-1990-2633","author":"Gonzales","year":"2023","journal-title":"Am J Perinatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-0042-1757279","volume":"39","author":"Manzoni","year":"2022","journal-title":"Am J Perinatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-0039-1691771","volume":"36","author":"Priante","year":"2019","journal-title":"Am J Perinatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s10096-012-1617-7","volume":"31","author":"Paes","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00431-011-1654-8","volume":"171","author":"Paes","year":"2012","journal-title":"Eur J Pediatr"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s10096-016-2891-6","volume":"36","author":"Resch","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s10096-003-0961-z","volume":"22","author":"Groothuis","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1936","volume":"37","author":"Kua","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/21645515.2020.1809265","volume":"17","author":"Takeuchi","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref55","volume-title":"Manual of Childhood Infections (Oxford Specialist Handbooks in Paediatrics): The Blue Book","year":"2016"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.chest.2020.02.075","volume":"158","author":"Amitai","year":"2020","journal-title":"Chest"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15050","volume":"15","author":"Wang","year":"2011","journal-title":"Health Technol Assess"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta12360","volume":"12","author":"Wang","year":"2008","journal-title":"Health Technol Assess"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","volume":"368","author":"Wu","year":"2007","journal-title":"J Mol Biol"},{"key":"ref61","first-page":"398","volume":"15","author":"O\u2019Brien","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","volume":"73","author":"Sim\u00f5es","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref63","unstructured":"Regeneron. Press Release: Regeneron to discontinue development of suptavumab for respiratory syncytial virus; 2017. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-discontinue-development-suptavumab-respiratory. Accessed June 22, 2023."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/INF.0000000000001916","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1126\/scitranslmed.aaj1928","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"ref66","unstructured":"Sandofi. Press Release: European Commission grants first approval worldwide of Beyfortus\u00ae (nirsevimab) for prevention of RSV disease in infants; 2022. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-discontinue-development-suptavumab-respiratory. Accessed July 13, 2023."},{"key":"ref67","unstructured":"GOV.UK. Independent report. Respiratory Syncytial virus (RSV) immunisation programme: JCVI advice; 2023. Available from: https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-programme-jcvi-advice-7-june-2023\/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023. Accessed July 13, 2023."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"ref70","unstructured":"St George\u2019s Vaccine Institute (SGVI). Harmonie RSV Study. A Phase IIIb randomised open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus in infants (HARMONIE); 2023. Available from: https:\/\/vaccine.ac.uk\/research\/harmonie-study\/. Accessed June 19, 2023."},{"key":"ref71","unstructured":"Sandofi. Press release: nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting; 2023. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-05-12-08-50-00-2667568. Accessed July 13, 2023."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","volume":"10","author":"Tang","year":"2019","journal-title":"Nat Commun"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ebiom.2021.103651","volume":"73","author":"Maas","year":"2021","journal-title":"eBioMedicine"},{"key":"ref74","unstructured":"RSV vaccine and mAb snapshot; 2022. Available from: https:\/\/www.path.org\/resources\/rsv-vaccine-and-mab-snapshot\/. Accessed April 23, 2023."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/bmj.p1021","volume":"381","author":"Boytchev","year":"2023","journal-title":"BMJ"},{"key":"ref78","unstructured":"GSK. GSK provides further update on Phase III RSV maternal vaccine candidate programme; 2022. Available from: www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-further-update-on-phase-iii-rsv-maternal-vaccine-candidate-programme. Accessed June 23, 2023."},{"key":"ref79","unstructured":"FDA. Sponsor briefing document vaccines and related biological products advisory committee meeting date: February 28-March 1, 2023. Available from: www.fda.gov\/media\/165621\/download#page=42. Accessed June 23, 2023."}],"container-title":["Drug, Healthcare and Patient Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92659","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:50:20Z","timestamp":1694404220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/review-of-the-safety-efficacy-and-tolerability-of-palivizumab-in-the-p-peer-reviewed-fulltext-article-DHPS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":79,"URL":"https:\/\/doi.org\/10.2147\/dhps.s348727","relation":{},"ISSN":["1179-1365"],"issn-type":[{"value":"1179-1365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}